Compare D R Horton Inc (DHI) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Nuwellis Inc — how do they compare? D R Horton Inc trades at $135.82 (market cap $37.99B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: D R Horton Inc is far larger — about 17268.2× Nuwellis Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Nuwellis Inc for 26 Days on average.
| DHI | NUWE | |
|---|---|---|
Market Cap | $37.99B | $2.20M |
Volume | 2,974,460 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $146.65 |
52-Week Low | $132.53 | $0.68 |
Typical Hold Time | 46 Days | 26 Days |
Enterprise Value | $43.09B | -$1.52M |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) is trading at $133.28, down 2.54% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 12.71 and P/S of 1.16, while maintaining solid profitability with 9.15% net margin. Recent earnings have consistently beaten expectations, though revenue declined to $34.25B in 2025. Technical indicators show oversold conditions with RSI at 26.75, while analyst consensus remains positive with $156.57 price target.
DHI presents a value opportunity with strong fundamentals but faces near-term headwinds from rising mortgage rates and housing market weakness. The 47% upside to consensus target offers potential reward, though investors must weigh housing sector volatility against the company's consistent execution and shareholder returns including dividends and buybacks.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
